

Special Issue

Cellular and Humoral Immunity after COVID-19 Vaccination

Message from the Guest Editor

This Special Issue of *the Vaccines* will summarize the current state of knowledge, fields to explore in particular referring (but not limited to) the following issues:

- cellular and humoral response in immunocompetent and immunocompromised population.
- differences in the immune response between vaccines
- duration of specific humoral and cellular immunity after primary and booster vaccination
- schemes of vaccination enhancing immune responses in immunocompromised patients
- comparing immune response after vaccination with the natural immunity of convalescents
- local and systemic reactogenicity and long-term safety of different vaccines

In this Special Issue, original research articles and reviews are welcome. We look forward to your contributions.

Guest Editor

Prof. Dr. Leszek Tylicki

Department of Nephrology, Transplantology and Internal Medicine,
Medical University of Gdańsk, 80-210 Gdańsk, Poland

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



mdpi.com/si/101660

Vaccines

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

vaccines@mdpi.com

[mdpi.com/journal/](http://mdpi.com/journal/vaccines)

[vaccines](http://vaccines.mdpi.com)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

